EUVIMEDEUVIMED entdecken
Crossref

Major role of dolutegravir in the emergence of the S147G integrase resistance mutation

Marc Wirden iD, Basma Abdi iD, Sidonie Lambert-Niclot iD, Marie-Laure Chaix iD, Anne De Monte, Brigitte Montes, Coralie Pallier, Pantxika Bellecave, Magali Bouvier-Alias, Stephanie Raymond iD, Sabine Yerly, Charlotte Charpentier und 3 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Marc Wirden und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universi…. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Drug Resistance, Viral, HIV-1, HIV Infections. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Agence Nationale de Recherches sur le SIDA et les Hépatites virales-Maladies Infectieuses Emergentes, Agence Nationale de Recherches sur le SIDA et les Hépatites virales—Maladies Infectieuses Emergentes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir. Given the widespread use of dolutegravir, further studies of S147G are required.

Methods

We consulted the HIV-1 resistance databases of French laboratories to identify all cases of S147G emergence. We collected immunological and virological parameters, history of treatment and INSTI resistance mutations. Mann–Whitney and Fisher’s exact tests were performed.

Results

We retrospectively identified 88 cases of S147G selection, from 2015 to 2022, in 22 laboratories. The most frequent HIV-1 subtypes were Clade B (55.7%) and CRF02_AG (21.6%). At the time of resistance genotyping, the median viral load was 5860 copies/mL (IQR 1011–24 525) and the median CD4 cell count was 412 cells/mm3 (228–560). S147G emerged on dolutegravir (48%), elvitegravir (36%) and raltegravir (10%) treatments. S147G was associated with a larger median number of other INSTI mutations on dolutegravir than on elvitegravir [3.0 (2.0–4.0) versus 2.0 (1.0–2.0); P = 0.0002] and was never observed with Q148H or G118R. On dolutegravir, S147G was associated principally with T97A (62%), N155H (59%), E138K (50%), L74I/M (38%) and Q148R (33%).

Conclusions

In this French study, S147G emerged principally in patients on dolutegravir regimens, in association with up to five other INSTI resistance mutations. This accumulation of mutations suggests a replicative advantage on HIV strains under dolutegravir selection pressure, suggesting that caution is required when interpreting dolutegravir resistance in the presence of such S147G resistance patterns, even in patients prescribed dolutegravir twice daily.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingDrug Resistance, ViralHIV-1HIV InfectionsHIV IntegraseHIV Integrase InhibitorsPiperazinesPyridonesOxazinesHumansRetrospective StudiesMaleFranceFemaleMutationMiddle AgedQuinolonesAdultGenotypeViral LoadDolutegravir

Substanzen

Heterocyclic Compounds, 3-RingPiperazinesPyridonesOxazinesHIV IntegraseHIV Integrase InhibitorsQuinolonesDolutegravirelvitegravir

Autor:innen und Institutionen

  • Department of Virology, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, 83 Boulevard de l'Hôpital 39,…
  • Department of Virology, AP-HP, CHU Saint Antoine, INSERM, Sorbonne Universités, UPMC Univ Paris 06, UMR-S 1136, Paris, France.
  • Department of Virology, INSERM U941, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France.
  • Department of Virology, CHU de Nice, Nice, France.
  • Department of Virology, CHU Montpellier, Univ Montpellier, F-34295 Montpellier, France.
  • Department of Virology, CHU Paul Brousse, Villejuif, France.

ORCID-Profile: Marc Wirden, Basma Abdi, Sidonie Lambert-Niclot, Marie-Laure Chaix, Stephanie Raymond

Förderung

  • Agence Nationale de Recherches sur le SIDA et les Hépatites virales-Maladies Infectieuses Emergentes
  • Agence Nationale de Recherches sur le SIDA et les Hépatites virales—Maladies Infectieuses Emergentes

Zitieren

APA

Wirden, M., Abdi, B., Lambert-Niclot, S., Chaix, M. L., De Monte, A., Montes, B., Pallier, C., Bellecave, P., Bouvier-Alias, M., Raymond, S., Yerly, S., Charpentier, C., Calvez, V., Descamps, D., & Marcelin, A. G. (2025). Major role of dolutegravir in the emergence of the S147G integrase resistance mutation. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae457

Vancouver

Wirden M, Abdi B, Lambert-Niclot S, Chaix ML, De Monte A, Montes B, et al. Major role of dolutegravir in the emergence of the S147G integrase resistance mutation. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae457

BibTeX
@article{Wirden2025,
  author = {Wirden, Marc and Abdi, Basma and Lambert-Niclot, Sidonie and Chaix, Marie-Laure and De Monte, Anne and Montes, Brigitte and Pallier, Coralie and Bellecave, Pantxika and Bouvier-Alias, Magali and Raymond, Stephanie and Yerly, Sabine and Charpentier, Charlotte and Calvez, Vincent and Descamps, Diane and Marcelin, Anne-Genevieve},
  title = {Major role of dolutegravir in the emergence of the S147G integrase resistance mutation},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae457}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche